DWTX — Dogwood Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1818844 ·
Last close
$1.42
Market Cap
$47.75M
52W High
$2.04
52W Low
$1.28
ADV30
95,366
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,076,366 | -4,986,614 | 95,207,871 | 13,227,839 | 14,584,519 |
| Dec 2025 | 0 | — | -3,806,279 | -3,780,449 | 90,171,237 | 6,524,744 | 15,274,370 |
| Sep 2025 | 0 | — | -15,809,125 | -15,744,616 | 91,992,613 | 10,126,710 | 14,607,504 |
| Jun 2025 | 0 | — | -3,923,115 | -3,807,353 | 96,692,527 | 13,402,809 | 14,151,904 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,523,284
Investing CF
—
Financing CF
$11,203,753
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-10.60
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-113,062,930
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-28,614,885
Pretax Income TTM
$-28,287,285
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -27,968,445 | -34,257,370 | 90,171,237 | 15,274,370 | — | -15,618,651 |
| Dec 2024 | 0 | -12,227,248 | -12,349,724 | 94,308,246 | 30,027,223 | — | -8,790,805 |
| Dec 2023 | 0 | -5,446,919 | -5,296,015 | 4,165,442 | 358,548 | — | -4,870,489 |
| Dec 2022 | 0 | -12,315,309 | -12,247,834 | 8,369,756 | 1,043,262 | — | -11,467,797 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-6.37
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IBO | IMPACT BIOMEDICAL INC. | $47.66M | $0.44 | — |
| VICP | Vicapsys Life Sciences, Inc. | $47.26M | $1.46 | — |
| HYPD | HYPERION DEFI, INC. | $46.84M | $3.09 | — |
| ETST | Earth Science Tech, Inc. | $46.11M | $0.16 | — |
| LTRN | Lantern Pharma Inc. | $45.93M | $3.60 | — |
News headlines (Yahoo Finance, 1h cache)
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
2026-06-30 12:45 · Yahoo
Chemotherapy-Induced Peripheral Neuropathy Market to Witness Significant Growth at a CAGR of 14.2% During the Forecast Period (2026-2036) as Novel Therapies Enter Late-Stage Development | DelveInsight
2026-06-16 16:31 · Yahoo
Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
2026-05-18 12:45 · Yahoo
Dogwood Therapeutics Announces First Quarter 2026 Financial Results
2026-05-14 12:30 · Yahoo
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
2026-05-07 12:30 · Yahoo
Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M
2026-04-23 13:00 · Yahoo
Dogwood Therapeutics, Inc. (DWTX) Advances SP16 Program with FDA Investigational New Drug Approval
2026-04-21 02:46 · Yahoo
Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
2026-04-15 13:00 · Yahoo
DWTX: 143 Patients Enrolled in Phase 2b Trial of Halneuron®; Results Expected in 3Q26
2026-03-23 11:18 · Yahoo
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
2026-03-18 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.